US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

DAMORA THERAPEUT

30.45

-0.3700-1.20%

Volume:244.85K

Turnover:7.53M

Market Cap:1.87B

PE:-3.08

High:31.49

Open:30.75

Low:29.70

Close:30.82

52wk High:38.33

52wk Low:2.45

Shares:61.55M

Float Shares:47.65M

Volume Ratio:0.75

T/O Rate:0.51%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-9.8764

EPS(LYR):-153.9532

ROE:-99.74%

ROA:-21.61%

PB:4.85

PE(LYR):-0.20

Loading ...

Overview Company News Filings

Damora Therapeutics Grants Inducement Stock Options for 453,500 Shares at USD 26.01 Each

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Analysts Have Conflicting Sentiments on These Healthcare Companies: Damora Therapeutics (DMRA), Summit Therapeutics (SMMT) and Elicio Therapeutics (ELTX)

Damora Therapeutics shareholders elect Landsittel, Turtle to board

Analysts Offer Insights on Healthcare Companies: Phibro Animal Health (PAHC) and Damora Therapeutics (DMRA)

Damora Therapeutics publishes DMR-001 mutant calreticulin antibody presentation

Damora Therapeutics Inc : H.c. Wainwright Initiates Coverage With Buy Rating; Price Target $45

THOMSON REUTERS

U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co, Datadog, Oracle

TD Cowen Initiates Damora Therapeutics at Buy

MT Newswires Live

Damora Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating

THOMSON REUTERS

U.S. RESEARCH ROUNDUP- Adobe, Allstate, Teleflex

Damora Therapeutics grants options for 372,000 shares to new hires at $24.88 each

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Damora Therapeutics Inc : Wedbush Initiates Coverage With Outperform Rating; Target Price $35

THOMSON REUTERS

Damora Therapeutics (DMRA) Receives a Rating Update from a Top Analyst

U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology

Damora Therapeutics Inc : Leerink Partners Cuts Target Price to $51 From $55

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Damora Therapeutics (DMRA) and vTv Therapeutics (VTVT)

RBC Capital Remains a Buy on Damora Therapeutics (DMRA)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/DMRA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"DMRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DMRA\",,,,,undefined,":{"symbol":"DMRA","market":"US","secType":"STK","nameCN":"DAMORA THERAPEUT","latestPrice":30.45,"timestamp":1787600454246,"preClose":30.82,"halted":0,"volume":244845,"delay":0,"changeRate":-0.012005191434133712,"floatShares":47648701,"shares":61553200,"eps":-9.876431,"marketStatus":"Trading","change":-0.37,"latestTime":"08-24 15:40:54 EDT","open":30.75,"high":31.4942,"low":29.7,"amount":7531828.359209999,"amplitude":0.058215,"askPrice":30.49,"askSize":200,"bidPrice":30.42,"bidSize":154,"shortable":3,"etf":0,"ttmEps":-9.876431,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"listingDate":1603944000000,"exchange":"NASDAQ","adjPreClose":30.82,"preHourTrading":{"tag":"盘前","latestPrice":30.874,"preClose":30.82,"latestTime":"08:14 EDT","volume":54,"amount":1664.334,"timestamp":1787573662148,"change":0.054,"changeRate":0.001752,"amplitude":0.001752},"postHourTrading":{"tag":"盘后","latestPrice":30.82,"preClose":30.82,"latestTime":"19:30 EDT","volume":2922,"amount":90051.84,"timestamp":1787355006251,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.747545},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DMRA\",,,,,undefined,":{"symbol":"DMRA","floatShares":47648701,"roa":"-21.61%","roe":"-99.74%","lyrEps":-153.953213,"volumeRatio":0.747545,"shares":61553200,"dividePrice":0,"high":31.4942,"amplitude":0.058215,"preClose":30.82,"low":29.7,"week52Low":2.45,"pbRate":"4.85","week52High":38.3251,"institutionHeld":0,"latestPrice":30.45,"committee":-0.129944,"eps":-9.876431,"divideRate":0,"volume":244845,"delay":0,"ttmEps":-9.876431,"open":30.75,"prevYearClose":23.01,"prevWeekClose":30.82,"prevMonthClose":28.99,"prevQuarterClose":26.01,"fiveDayClose":31.09,"twentyDayClose":29.44,"sixtyDayClose":24.84},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DMRA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-12","symbol":"DMRA","fiscalQuarterEnding":"2026/03","expectedEps":-0.21,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.62},{"market":"US","date":"2026-03-19","symbol":"DMRA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1773892800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-06","symbol":"DMRA","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-2.36},{"market":"US","date":"2025-08-05","symbol":"DMRA","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754366400000,"reportTimeType":"post","actualEps":-2.6},{"market":"US","date":"2025-05-08","symbol":"DMRA","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-1.92}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DMRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DMRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":10,"updateTime":1785124800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DMRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DMRA","date":"2026-08-21","current":-3.11651,"percent":0.571429,"low":-100.260711,"twenty":-7.785196,"median":-7.218207,"eighty":-6.321676,"high":-5.207587,"avg":-13.023094,"sd":22.005777,"marketCap":1871203580},"quantilePoints":[{"date":"2026-03-13","current":-100.260711,"twenty":-100.260711,"median":-100.260711,"eighty":-98.29884,"marketCap":1588530698},{"date":"2026-03-20","current":-72.999835,"twenty":-100.199878,"median":-95.983376,"eighty":-84.763454,"marketCap":1156609382},{"date":"2026-03-27","current":-7.36551,"twenty":-98.861547,"median":-80.41388,"eighty":-7.003988,"marketCap":1545571323},{"date":"2026-04-02","current":-7.207452,"twenty":-96.587906,"median":-7.443103,"eighty":-7.019507,"marketCap":1512404556},{"date":"2026-04-10","current":-7.670132,"twenty":-94.238224,"median":-7.361199,"eighty":-7.021806,"marketCap":1609492728},{"date":"2026-04-17","current":-7.759219,"twenty":-89.113027,"median":-7.443103,"eighty":-7.088477,"marketCap":1628186724},{"date":"2026-04-24","current":-7.305161,"twenty":-78.931071,"median":-7.519258,"eighty":-7.200555,"marketCap":1532907649},{"date":"2026-05-01","current":-7.374132,"twenty":-59.951712,"median":-7.420112,"eighty":-7.071235,"marketCap":1547380419},{"date":"2026-05-08","current":-7.181588,"twenty":-7.748873,"median":-7.369821,"eighty":-7.098823,"marketCap":1506977267},{"date":"2026-05-15","current":-6.125513,"twenty":-7.702318,"median":-7.328151,"eighty":-6.979849,"marketCap":1440040702},{"date":"2026-05-22","current":-6.376895,"twenty":-7.679328,"median":-7.296539,"eighty":-6.874668,"marketCap":1499137850},{"date":"2026-05-29","current":-6.50384,"twenty":-7.670132,"median":-7.208889,"eighty":-6.624282,"marketCap":1528981338},{"date":"2026-06-05","current":-5.841412,"twenty":-7.647141,"median":-7.181588,"eighty":-6.506459,"marketCap":1373251758},{"date":"2026-06-12","current":-5.592674,"twenty":-7.644267,"median":-7.103996,"eighty":-6.310202,"marketCap":1314776223},{"date":"2026-06-18","current":-5.608384,"twenty":-7.605184,"median":-7.036462,"eighty":-6.158347,"marketCap":1318469415},{"date":"2026-06-26","current":-5.909488,"twenty":-7.595413,"median":-6.974676,"eighty":-5.98699,"marketCap":1389255588},{"date":"2026-07-02","current":-7.092956,"twenty":-7.5092,"median":-6.96318,"eighty":-6.007936,"marketCap":1667476025},{"date":"2026-07-10","current":-8.059107,"twenty":-7.645417,"median":-7.006288,"eighty":-6.078901,"marketCap":1894607311},{"date":"2026-07-17","current":-7.917719,"twenty":-7.67473,"median":-7.092956,"eighty":-6.150138,"marketCap":1861368586},{"date":"2026-07-24","current":-7.637561,"twenty":-7.776537,"median":-7.12986,"eighty":-6.183485,"marketCap":1795506668},{"date":"2026-07-31","current":-7.648035,"twenty":-7.738833,"median":-7.190209,"eighty":-6.195797,"marketCap":1797968796},{"date":"2026-08-07","current":-7.82346,"twenty":-7.815082,"median":-7.208161,"eighty":-6.219919,"marketCap":1839209436},{"date":"2026-08-14","current":-7.218207,"twenty":-7.815082,"median":-7.209243,"eighty":-6.276357,"marketCap":1897132498},{"date":"2026-08-21","current":-7.119553,"twenty":-7.785196,"median":-7.218207,"eighty":-6.321676,"marketCap":1871203580}],"updateTime":1787594124346},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DMRA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2648251695","title":"Damora Therapeutics Grants Inducement Stock Options for 453,500 Shares at USD 26.01 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2648251695","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648251695?lang=en_us&edition=fundamental","pubTime":"2026-07-02 04:01","pubTimestamp":1782936076,"startTime":"0","endTime":"0","summary":"Damora Therapeutics grants inducement stock options for 453,500 shares at USD 26.01 eachDamora Therapeutics granted inducement stock options to nine newly hired, non-executive employees on July 1, 202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL5PShfg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","LU2210150020.SGD","SG9999014039.USD","SG9999014013.SGD","IE00BKPKM429.USD","BK4588","IE00B64PRP62.GBP","SG9999014005.SGD","BK4112","NDAQ","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014021.USD","LU0314104364.USD","BK4139","IE00B3QW5Z07.USD","DMRA","BK4585","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648525197","title":"Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2648525197","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648525197?lang=en_us&edition=fundamental","pubTime":"2026-07-02 04:01","pubTimestamp":1782936060,"startTime":"0","endTime":"0","summary":"BOSTON, July  01, 2026  (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/01/3320969/0/en/Damora-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DMRA","LENZ","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645026491","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Damora Therapeutics (DMRA), Summit Therapeutics (SMMT) and Elicio Therapeutics (ELTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645026491","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645026491?lang=en_us&edition=fundamental","pubTime":"2026-06-22 18:33","pubTimestamp":1782124427,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Damora Therapeutics (DMRA), Summit Therapeutics (S...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-damora-therapeutics-dmra-summit-therapeutics-smmt-and-elicio-therapeutics-eltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-damora-therapeutics-dmra-summit-therapeutics-smmt-and-elicio-therapeutics-eltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","LABU","XLV","BK4581","HCSG","XBI","LU0128526141.USD","BK4585","LU0029874061.USD","ELTX","BK4007","DMRA","LU2488822045.USD","BK4139","BK4588","SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644296287","title":"Damora Therapeutics shareholders elect Landsittel, Turtle to board","url":"https://stock-news.laohu8.com/highlight/detail?id=2644296287","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644296287?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:01","pubTimestamp":1781726460,"startTime":"0","endTime":"0","summary":"Damora Therapeutics held its annual stockholder meeting on June 17, 2026.Stockholders backed the board’s two director nominees, clearing their continued service through the 2029 annual meeting.Investors also endorsed an annual cadence for future advisory votes on executive pay; the board plans to hold those votes yearly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL1W9XC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642575295","title":"Analysts Offer Insights on Healthcare Companies: Phibro Animal Health (PAHC) and Damora Therapeutics (DMRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642575295","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642575295?lang=en_us&edition=fundamental","pubTime":"2026-06-12 21:10","pubTimestamp":1781269838,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Phibro Animal Health (PAHC) and Damora Therapeutics ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-phibro-animal-health-pahc-and-damora-therapeutics-dmra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-phibro-animal-health-pahc-and-damora-therapeutics-dmra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PAHC","BK4585","LU0029874061.USD","HCSG","LENZ","XBI","BK4539","BK4137","BK4581","XLV","BK4139","LABU","DMRA","BK4588","BK4007","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642094281","title":"Damora Therapeutics publishes DMR-001 mutant calreticulin antibody presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2642094281","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642094281?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:17","pubTimestamp":1781180279,"startTime":"0","endTime":"0","summary":"Damora Therapeutics published a preclinical research presentation on DMR-001, an Fc-null, half-life optimized monoclonal antibody targeting mutant calreticulin in ET and MF.Program highlights included binding affinity of 0.074 nM for Type 1 del52 mutCALR, 0.31 nM for Type 2 ins5.Non-human primate PK half-life was 15 days, versus 3.1 days for a reference mutCALR antibody; expected Phase 1 dosing SC Q4W.Data showed internalization of surface mutCALR, inhibition of pSTAT1 signaling, reduced proliferation; no ADCC or CDC activity reported.A Phase 1/1b study in mutCALR-driven MPN patients is planned to initiate in Q3 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL2jL0Yl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642283756","title":"Damora Therapeutics Inc : H.c. Wainwright Initiates Coverage With Buy Rating; Price Target $45","url":"https://stock-news.laohu8.com/highlight/detail?id=2642283756","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642283756?lang=en_us&edition=fundamental","pubTime":"2026-06-11 18:09","pubTimestamp":1781172549,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nFWN42J0AC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642402160","title":"U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co, Datadog, Oracle","url":"https://stock-news.laohu8.com/highlight/detail?id=2642402160","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642402160?lang=en_us&edition=fundamental","pubTime":"2026-06-11 15:59","pubTimestamp":1781164792,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co, Datadog, Oracle June 11 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nL4N42J0KA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BKH","NETG","BABA","GEV","GEVX","ORCS","ASO","AGIO","EQH","GKOS","INSM","CITR","AMDY","AMDW","AJG","CLOV","DMRA","FSLR","BABO","HNGE","GNRC","CPT","DDOG","INCY","NVST","NRGV","WMS","BBYY","HUMA","NET","EXTR","KBAB","CRBG","HSIC","AMAT","CTVA","CHWY","AXSM","CGEM","GD","CASY","ORCX","AMDD","ORCL","FE","CTBI","INTC","HIG","AMD","AMDG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641027483","title":"TD Cowen Initiates Damora Therapeutics at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2641027483","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641027483?lang=en_us&edition=fundamental","pubTime":"2026-06-08 18:20","pubTimestamp":1780914031,"startTime":"0","endTime":"0","summary":"Damora Therapeutics (DMRA) has an average rating of buy and mean price target of 43.14, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["COWN","BK4207","BK4566","LENZ","TD","BK4139","BK4007","BK4539","BK4127","DMRA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641937488","title":"Damora Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2641937488","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641937488?lang=en_us&edition=fundamental","pubTime":"2026-06-08 17:44","pubTimestamp":1780911840,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nFWN42G0C7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641772104","title":"U.S. RESEARCH ROUNDUP- Adobe, Allstate, Teleflex","url":"https://stock-news.laohu8.com/highlight/detail?id=2641772104","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641772104?lang=en_us&edition=fundamental","pubTime":"2026-06-08 16:01","pubTimestamp":1780905690,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Adobe, Allstate, TeleflexJune 8 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adobe, Allstate a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nL4N42G0LS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVS","ELV","ANEL","FCX","EQR","BTI","ASTS","ADBG","ALL","EXTR","ADBE","BXSL","APH","CSCO","CIEN","CSR","BXDC","AVNT","CNC","FIX","CPT","BK4512","LU0081259029.USD","ASTN","CI","EROK","BRCB","ESS","FCXG","CNCG","CENX","CSCS","DDOG","ANET","ETR","BIIB","AA","APHU","CMI","AVB","CSCL","APGE","CQP","CTSH","FRT","ASTX","DOGD","DMRA","CBT","CBRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640495926","title":"Damora Therapeutics grants options for 372,000 shares to new hires at $24.88 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2640495926","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640495926?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:02","pubTimestamp":1780315321,"startTime":"0","endTime":"0","summary":"Damora Therapeutics granted non-qualified stock options covering 372,000 shares to six newly hired, non-executive employees on June 1, 2026.Options carry a 10-year term with an exercise price of USD 24.88 per share.Vesting starts with 25% on the first anniversary of each employee’s start date, then monthly over the next 36 months.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL5nMMbh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","DMRA","LU2095319765.USD","BK4588","IE00B64PRP62.GBP","SG9999014005.SGD","NDAQ","SG9999014021.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","SG9999014039.USD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014013.SGD","BK4139","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640095917","title":"Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640095917","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640095917?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:00","pubTimestamp":1780315205,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUACGPDTB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DMRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640006959","title":"Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640006959","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640006959?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:00","pubTimestamp":1780315200,"startTime":"0","endTime":"0","summary":"BOSTON, June  01, 2026  (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304320/0/en/Damora-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMRA","BK4539","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638666780","title":"Damora Therapeutics Inc : Wedbush Initiates Coverage With Outperform Rating; Target Price $35","url":"https://stock-news.laohu8.com/highlight/detail?id=2638666780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638666780?lang=en_us&edition=fundamental","pubTime":"2026-05-28 18:52","pubTimestamp":1779965532,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nFWN4250AY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636018490","title":"Damora Therapeutics (DMRA) Receives a Rating Update from a Top Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2636018490","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636018490?lang=en_us&edition=fundamental","pubTime":"2026-05-18 00:48","pubTimestamp":1779036480,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Damora Therapeutics yesterday and set a price target of $45.00. Slutsky covers the H...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/damora-therapeutics-dmra-receives-a-rating-update-from-a-top-analyst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/damora-therapeutics-dmra-receives-a-rating-update-from-a-top-analyst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DMRA","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635358799","title":"U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2635358799","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635358799?lang=en_us&edition=fundamental","pubTime":"2026-05-14 15:24","pubTimestamp":1778743446,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology May 14 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cisc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL4N41R0NP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRVU","APGE","DELL","CSR","CIFG","AFRM","AVTX","BXP","CVNX","CPT","CMC","ASO","CMP","CAVA","DTE","AVB","CIFR","CMS","DMRA","CSCL","DOCS","DECK","CAKE","CVNY","CIFU","AEE","ATLC","CSCO","AFRU","ANTX","AMGN","CLH","AN","ET","ANDG","MRVL","CARR","CORZ","CSCS","DLLL","EBAY","MVLL","CGON","ARMK","AKAM","ARVN","ASTH","CVNA","DT","ABBV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635769831","title":"Damora Therapeutics Inc : Leerink Partners Cuts Target Price to $51 From $55","url":"https://stock-news.laohu8.com/highlight/detail?id=2635769831","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635769831?lang=en_us&edition=fundamental","pubTime":"2026-05-14 11:24","pubTimestamp":1778729084,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nFWN41Q19H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635750222","title":"Analysts Offer Insights on Healthcare Companies: Damora Therapeutics (DMRA) and vTv Therapeutics (VTVT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635750222","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635750222?lang=en_us&edition=fundamental","pubTime":"2026-05-14 09:00","pubTimestamp":1778720410,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Damora Therapeutics (DMRA) and vTv Therapeutics (VTV...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-damora-therapeutics-dmra-and-vtv-therapeutics-vtvt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-damora-therapeutics-dmra-and-vtv-therapeutics-vtvt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","XLV","BK4581","LU0029874061.USD","BK4585","BK4588","VTVT","XBI","BK4139","BK4137","HCSG","DMRA","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635781639","title":"RBC Capital Remains a Buy on Damora Therapeutics (DMRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635781639","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635781639?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:38","pubTimestamp":1778672322,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Damora Therapeutics, with a price target of $40.00. The ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-damora-therapeutics-dmra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-damora-therapeutics-dmra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1267930573.SGD","LU0310800379.SGD","LENZ","LU0708994859.HKD","BK4539","BK4207","LU0128525929.USD","BK4139","LU0029864427.USD","DMRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":72,"code":"91000000","status":"200"}]}}